Search PubMed⌕ Search

Biomedical subjects

J Ferrer

Publications and source records attributed to J Ferrer.

At least 163 records · Page 9Linked to original sources
PubMed1990

Primary intrapulmonary benign schwannoma. A case with ultrastructural and immunohistochemical confirmation.

Neurogenic pulmonary tumours are rare. Neurofibromas are the most common variety and tend to occur in patients with generalized neurofibromatosis, whereas schwannomas arise sporadically in patients who have no evidence of this disorder. A case of solitary benign schwannoma arising in a segmental bronchus is presented, and the published cases reviewed. Microscopically, the tumour had a spindle-shaped cell proliferation with palisade formation in several fields and low cellularity in other areas. The diagnosis was supported by positive immunostaining for S-100 protein and by ultrastructural examination which showed elongated cells surrounded by well-preserved basal lamina and numerous cytoplasmic processes also possessing a basal lamina.

Aged↗
PubMed1989

[Evaluation of the treatment of Cushing's syndrome using ketoconazole].

The effectiveness of ketoconazole for the therapy of Cushing's syndrome, both of adrenal and pituitary origin, was retrospectively evaluated. To this end, the clinical and hormonal results in 5 patients were assessed. There were 4 females and one male, with ages ranging between 17 and 64 years. Three of them, who had Cushing's disease, received sustained treatment with ketoconazole when other therapeutic measures had failed. The two remaining patients (one with Cushing's disease and the other with adrenal adenoma) were treated with this drug in the preoperative period to alleviate the deterioration in the clinical condition caused by hypercortisolism. The clinical evolution of the patients is described, as well as the plasma adrenocorticotropin (ACTH) and the free cortisol in 24 hour urine in the subsequent controls. In view of the study results, we feel that ketoconazole is an effective treatment for the long term control of Cushing's syndrome. In addition, it may be also useful as preoperative therapy in those patients severely deteriorated by the sustained hypercortisolism.

Adolescent↗
PubMed1989

[Thrombosis of the superior vena cava as an early manifestation of Behçet's disease. Presentation of 2 cases].

The vascular involvement of Behçet's disease is nowadays considered as an important sign of the clinical evolution of these patients. It can affect both the arterial and the venous territories. Superficial thrombophlebitis is the most common vascular manifestation. Thrombosis of deep veins is relatively rare and it generally appears within the inferior vena cava territory as a late manifestation in the evolution of the disease. We describe two cases of Behçet's disease which presented, at an early stage, thrombosis of the superior vena cava as the more relevant manifestation of the disease. The evolution of both patients was satisfactory with the combination of cyclophosphamide and colchicine. The etiopathogenesis of this manifestation and its therapeutic possibilities are discussed.

Adolescent↗
PubMed1988

[Computerized clinical protocol for occlusion].

In making a protocol it is necessary that all members of the team who are going to collect information have the same unity of criterion about the different variables that compose it. The drawing up of this document is as much or more necessary than the protocol itself. In this work we all data collected in the protocol and we give the explanations of each concept.

Diagnosis, Computer-Assisted↗
PubMed1986

Acute, short- and long-term efficacy of oral bevantolol in patients with coronary artery disease: a placebo-controlled, randomized, double-blind study.

The efficacy and safety of bevantolol (new cardioselective beta-blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris. Acute effects on heart rate (HR) and pulmonary function (forced expiratory volume in the first second, FEV1, and vital capacity, VC) (double-blind placebo, propranolol, 80 mg, and bevantolol, 150 mg) and the antianginal efficacy during early (double-blind placebo period) and chronic bevantolol therapy (long-term follow-up for 52 weeks) were studied. Bevantolol reduces HR in the same way as propranolol (both p less than 0.01). Pulmonary function is modified significantly only by propranolol (decreasing FEV1, p less than 0.05). Bevantolol reduces antianginal attacks and nitroglycerin consumption (p less than 0.01) and improves exercise tolerance (p less than 0.01) during early and chronic therapy.

Administration, Oral↗